Incidence of serious gastrointestinal events and inflammatory bowel disease among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: Data from 3 large randomized clinical trials

被引:0
|
作者
Gooderham, Melinda [1 ]
Elewski, Boni [2 ]
Pariser, David [3 ,4 ]
Sofen, Howard [5 ]
Mendelsohn, Alan [6 ]
Cichanowitz, Nicole [7 ]
Li, Qing [7 ]
la Rosa, Carmen [7 ]
机构
[1] Prob Med Res & Skin Ctr Dermatol, Peterborough, ON, Canada
[2] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA
[3] Eastern Virginia Med Sch, Williamsburg, VA USA
[4] Virginia Clinical Res Inc, Norfolk, VA USA
[5] Univ Calif Los Angeles, Dept Med Dermatol, Los Angeles, CA 90024 USA
[6] Sun Pharmaceut, Philadelphia, PA USA
[7] Merck & Co Inc, Kenilworth, NJ USA
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
7092
引用
收藏
页码:AB166 / AB166
页数:1
相关论文
共 50 条
  • [1] Incidence of Serious Gastrointestinal Events and Inflammatory Bowel Disease Among Tildrakizumab-Treated Patients with Moderate to Severe Plaque Psoriasis: Data from 3 Large Randomized Clinical Trials
    Gooderham, Melinda
    Elewski, Boni E.
    Pariser, David M.
    Sofen, Howard
    Mendelsohn, Alan M.
    Cichanowitz, Nicole
    Li, Qing
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AND INFLAMMATORY BOWEL DISEASE AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: DATA FROM 3 LARGE RANDOMISED CLINICAL TRIALS
    Gooderham, M.
    Elewski, B. E.
    Pariser, D. M.
    Sofen, H.
    Mendelsohn, A. M.
    Cichanowitz, N.
    Li, Q.
    La Rosa, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 364 - 364
  • [3] Incidence of serious gastrointestinal events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Data from 3 randomized clinical trials
    Gooderham, M.
    Elewski, B.
    Pariser, D.
    Sofen, H.
    Mendelsohn, A.
    Li, Q.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 63 - 63
  • [4] Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials
    Bissonnette, Robert
    Fernandez-Penas, Pablo
    Puig, Lluis
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB79 - AB79
  • [5] Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (01) : E21 - E24
  • [6] INCIDENCE OF SERIOUS GASTROINTESTINAL EVENTS AMONG TILDRAKIZUMAB-TREATED PATIENTS WITH PSORIASIS
    Gooderham, Melinda
    Elewski, Boni E.
    Pariser, David M.
    Sofen, Howard
    Mendelsohn, Alan M.
    Cichanowitz, Nicole
    Li, Qing
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 24 - 24
  • [7] Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis
    Gooderham, M.
    Elewski, B. E.
    Pariser, D. M.
    Sofen, H.
    Mendelsohn, A. M.
    Rozzo, S. J.
    Li, Q.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (10) : E350 - E352
  • [8] Incidence of cardiovascular events among tildrakizumab-treated patients with psoriasis: Pooled data from 3 large randomized clinical trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 62 - 62
  • [9] Incidence of infections in clinical trials of tildrakizumab for moderate-to-severe chronic plaque psoriasis
    Crowley, Jeffrey
    Leonardi, Craig
    Sturgill-Koszycki, Sheila
    Menter, Alan
    Mendelsohn, Alan M.
    Li, Qing
    Cichanowitz, Nicole
    Gree, Stuart
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB166 - AB166
  • [10] Incidence of cardiovascular events in patients with moderate-to-severe plaque psoriasis treated with tildrakizumab: pooled analysis from a phase 2 and two phase 3 trials
    Bissonnette, R.
    Fernandez-Penas, P.
    Puig, L.
    Peserico, A.
    Fumero, E.
    Mendelsohn, A.
    Rozzo, S.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 46 - 47